- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-03-01-2018
Pharmaceutical Executive
Pharma: Meet Your New Neighbors
March 20, 2018
Features
38
3
Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.
Risk Sharing, Italian Style
March 19, 2018
Features
38
3
Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale
The Quest to Measure Up
March 16, 2018
Features
38
3
Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.
Full Disclosure Demanded for Pharma Industry
March 07, 2018
Columns
38
3
The public and policymakers seek more transparency in pricing and product development.
Setting the Standard: William Soliman, ACMA
March 07, 2018
Columns
38
3
How one pharma vet helped create the first industry-wide training standards for aspiring medical affairs professionals.
The Law of Unintended Consequences
March 07, 2018
From the Editor
38
3
Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.
A Bold Path Etched in DNA
March 07, 2018
Features
38
3
Markus Warmuth, CEO of cancer genomics company H3 Biomedicine, speaks with Pharm Exec about being part of a new wave of biotech business leaders, who let the science chart the course.
Pricing Turning Point: The Case for Innovating Pharma’s Model
March 06, 2018
Features
38
3
Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Showdown Nears on Europe Research Incentives
March 01, 2018
Columns
38
3
Scope of supplementary protection certificate (SPC) could change.
The Personalized Genetic Profile: It’s Time to Align
March 01, 2018
Columns
38
3
Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Country Report: India
March 01, 2018
Special Sponsored Section
38
3
The global importance of the Indian pharmaceutical industry and the affordable generic drugs it produces is indisputable. But despite its evolving international role, India’s domestic healthcare system remains underperforming and undercapitalized.
Pharmaceutical Executive, March 2018 Issue (PDF)
March 01, 2018
Issue PDF
38
3
Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.